Transplantation by Hall, Erin C et al.
Association of Antibody Induction Immunosuppression with 
Cancer After Kidney Transplantation1
Erin C Hall, MD MPH2,3, Eric A Engels, MD MPH3, Ruth M Pfeiffer, PhD3, and Dorry L Segev, 
MD PhD2,4
2Department of Surgery, Johns Hopkins School of Medicine, 720 Rutland Ave, Baltimore MD 
21205
3Division of Cancer Epidemiology and Genetics, National Cancer Institute, 9609 Medical Center 
Dr, Bethesda, MD 20892
4Department of Epidemiology, Johns Hopkins School of Public Health, Baltimore MD 21205
Abstract
Background—Induction immunosuppression is a mainstay of rejection prevention after 
transplantation. Studies have suggested a connection between antibody induction agents and 
cancer development, potentially limiting important immunosuppression protocols.
Methods—We used a linkage of U.S. transplantation data and cancer registries to explore the 
relationship between induction and cancer after transplantation. 111,857 kidney recipients (1987–
2009) in the Transplant Cancer Match Study, which links the Scientific Registry for Transplant 
Recipients and U.S. cancer registries, were included. Poisson regression models were used to 
estimate adjusted incidence rate ratios (aIRR) of non-Hodgkin lymphoma (NHL)and other cancers 
with increased incidence after transplantation (lung, colorectal, kidney, and thyroid cancers, plus 
melanoma).
Results—2,763 cancers of interest were identified. Muromonab-CD3 was associated with 
increased NHL (aIRR=1.37, 95% CI 1.06–1.76). Alemtuzumab was associated with increased 
NHL (aIRR=1.79, 95% CI 1.02-1-3.14), colorectal cancer (aIRR=2.46, 95% CI 1.03–5.91), and 
thyroid cancer (aIRR=3.37, 95% CI 1.55–7.33). Polyclonal induction was associated with 
increased melanoma (aIRR=1.50, 95% CI 1.06–2.14).
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Conclusions—Our findings highlight the relative safety with regard to cancer risk of the most 
common induction therapies, the need for surveillance of patients treated with alemtuzumab, and 
the possible role for increased melanoma screening for those patients treated with polyclonal anti-
T cell induction.
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Introduction
Cancer is the third most common cause of death after kidney transplantation. (1) When 
compared to the general population, transplant recipients have increased risk for dozens of 
malignancies (2,3) and have higher mortality rates due to cancer when compared to the 
general population. (4) The immunosuppression that transplant recipients must receive in 
order to prevent rejection is thought to increase cancer risk through decreased control of 
oncogenic viral infections and immunosurveillance similarly to other immunosuppressed 
populations. (3) Antibody induction agents are a potent group of immunosuppressive 
therapies that reduce the risk of rejection primarily through T-cell depletion or modulation; 
these agents are a mainstay of acute rejection prevention for many kidney transplant 
recipients. (5,6) Use of induction immunosuppression and the agent chosen are potentially 
modifiable risk factors for cancer after transplantation, however the associations between 
antibody immunomodulation and cancer after transplantation remain poorly understood.
Some studies have suggested an association between antibody induction and cancer after 
transplantation, (7–11) while others have failed to demonstrate this association. (12–15) 
These conflicting results may be due to differences in categorization of induction agents, the 
time period covered, and cancer outcomes of interest. Small sample sizes have forced 
researchers to group together different antibody induction agents and cancer outcomes. 
These heterogeneous exposures and outcomes make it difficult to gain mechanistic 
understanding of the role of induction immunosuppression and cancer risk, and offer little 
guidance to clinicians. Furthermore, antibody induction agents with novel mechanisms, such 
as alemtuzumab, remain mostly uninvestigated in terms of cancer risk after transplantation. 
The few studies that do exist have similar limitations to other studies of induction and cancer 
risk: only post-transplant lymphoproliferative disorder (PTLD) has been examined, 
inferences are limited by relatively short follow-up time, and results have been 
contradictory. (11,16)
One way to address this sample size problem is to use the data collected by the US-wide 
Organ Procurement and Transplantation Network (OPTN) and contained in the Scientific 
Registry of Transplant Recipients (SRTR). While capture of recipient, donor, transplant, and 
in-hospital immunosuppression data are excellent in this database, a reliance on transplant 
center reporting of cancer outcomes causes known limitations in cancer ascertainment. (17) 
Previous studies using OPTN data to explore cancer risk associated with antibody induction 
have, because of the nature of limited cancer ascertainment in the registry, censored follow-
up at three years post-transplant and limited the outcome of interest to early PTLD, 
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curtailing the potential power of this registry and still producing conflicting inferences. 
(10,11,14,15)
To improve inferences about the association between specific antibody induction agents and 
cancers after kidney transplantation, we used the recent, population-based Transplant Cancer 
Match (TCM) Study. Unlike previous U.S.-based studies, the TCM Study takes advantage 
of mandatory cancer reporting to state and regional cancer registries, capturing cancers in 
transplant recipients that occur after the transplant center loses follow-up. Using the TCM 
data, we tested our hypothesis that antibody induction immunosuppression is most 
associated with those cancers that are known to be virus-related, including non-Hodgkin 
lymphoma (NHL). We were also able to investigate the association between antibody 
induction immunosuppression and common non-virus-related cancers including lung cancer, 
kidney cancer, colorectal cancer, thyroid cancer, and melanoma (among non-Hispanic white 
recipients). The size of this study allowed for categorization of antibody induction exposures 
and cancer outcomes that are clinically and mechanistically relevant. The availability of high 
quality data over 20 years allowed us to take into account changes in antibody induction use 
over time. Our results could help guide clinician decision making with regard to risks and 
benefits of antibody induction and the need for screening in kidney recipients who received 
induction immunosuppression. In addition, characterization of the risk of specific cancers 
associated with mechanistically relevant categorization of induction immunosuppression 
may provide new insights into cancer development.
Results
Study Population
Cancer registry linkage was available for 111,857 kidney recipients who met inclusion 
criteria, with a median follow-up of 3.5 years (range: 1 day to 21.7 years, IQR: 1.4–6.5 
years). Approximately half of kidney recipients (53.6%) were treated with an antibody 
induction agent. Demographics of those receiving each induction agent varied only slightly 
(Table 1). Of those receiving polyclonal antibodies, a higher percentage were of black race 
(26.2%) or undergoing retransplantation (14.2%). A higher percentage of those receiving 
muromonab-CD3 were 18–35 years old (25.7%) and a lower percentage had zero HLA 
mismatches (9.1%) or received kidneys from living donors (16.3%) compared to other 
induction agents.
Temporal Trends in Induction
Use of antibody induction, as well as the agents used, changed over time (Figure 1). Among 
induction agents used, the proportion of recipients receiving polyclonal anti-T cell agents 
increased from 22.6% to 66.4%. Likewise, anti-IL2R usage increased since its introduction 
in 1995 from 0.4% to 22.4%. The peak use of muromonab-CD3 occurred in the early 1990s 
with rapidly decreasing proportion of recipients receiving this agent after 1999. 
Alemtuzumab was introduced in 2000 and its use remains relatively uncommon (6.9% of 
recipients between 2002 and 2009).
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Associations with induction agents are shown for virus-related cancers (Table 2) and other 
cancers (Table 3). Polyclonal anti-T cell induction was not associated with NHL 
(aIRR=0.96, 95% CI 0.77–1.20, p=0.7 and), non-NHL VRCs (aIRR=1.11, 95% CI 0.82–
1.53, p=0.5 and), or all VRCs (aIRR=1.01, 95% CI 0.84–1.21, p=0.9). Polyclonal anti-T cell 
induction was associated with increased melanoma among non-Hispanic whites (aIRR=1.50, 
95% CI 1.06–2.14, p=0.02); when restricted to transplant recipients between 2000 and 2009, 
this association was of similar magnitude but no longer statistically significant (aIRR 1.52, 
95% CI 0.85–2.69, p=0.2). Similarly, when restricted to those patients who received rabbit 
anti-thymocyte globulin, the association persisted, but was no longer statistically significant 
(aIRR 1.65, 95% CI 0.97–2.82, p=0.06). Polyclonal anti-T cell induction was not associated 
with lung, kidney, colorectal, or thyroid cancers after transplantation.
Muromonab-CD3
Among VRCs, muromonab-CD3 induction was associated with increased NHL (aIRR=1.37, 
95% CI 1.06–1.76, p=0.02) and all VRCs (aIRR 1.29, 95% CI 1.04–1.60, p=0.02) (Table 2). 
This association with NHL did not change with time from transplant (p-value of 
interaction=0.3). Muromonab-CD3 induction was not associated with non-NHL VRCs 
(aIRR=1.02, 95% CI 0.65–1.58, p=0.9), suggesting that its association with all VRCs was 
driven by its association with NHL. Among non-VRCs, muromonab-CD3 induction was 
associated with decreased thyroid cancer (aIRR=0.32, 95% CI 0.12–0.80, p=0.01) (Table 3). 
Muromonab-CD3 induction was not associated with lung, kidney, colorectal cancers, or 
melanoma after transplantation.
Alemtuzumab
Alemtuzumab induction was also associated with increased NHL (aIRR=1.79, 95% CI 1.02–
3.14, p=0.04) and all VRCs (aIRR=1.84, 95% CI 1.11–3.03, p=0.02). The association with 
NHL did not change with time from transplant (p-value of interaction =0.1). Among non-
VRCs, alemtuzumab induction was associated with increased colorectal cancer (aIRR=2.46, 
95% CI 1.03–5.91, p=0.04) and thyroid cancer (aIRR=3.37, 95% CI 1.55–7.33, p=0.002). 
Alemtuzumab induction was not associated with lung, kidney cancer, or melanoma after 
transplantation.
IL2 Receptor Antagonists
Anti-IL2R induction was not associated with NHL (aIRR=0.82, 95% CI 0.65–1.05, p=0.1), 
non-NHL VRCs, (aIRR 1.09, 95% CI 0.78–1.51, p=0.6), or all VRCs (aIRR=0.90, 95% CI 
0.74–1.10, p=0.3). Among non-VRCs, anti-IL2R induction was associated with decreased 
lung cancer (aIRR=0.73, 95% CI 0.56–0.95, p=0.02). Anti-IL2R induction was not 
associated with kidney, colorectal, thyroid cancers, or melanoma after transplantation.
Discussion
In this U.S.-wide study of 111,857 kidney recipients linked to mandatory cancer reporting 
systems, commonly used antibody induction agents were not associated with increased 
cancer after kidney transplantation, with the exception of 50% increased melanoma 
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associated with polyclonal anti-T cell induction. Two infrequently used agents were 
associated with increased cancer:muromonab-CD3 induction was associated with 37% 
increased NHL, and alemtuzumab induction was associated with 79% increased NHL, a two 
and a half fold increase in colorectal cancer, and three fold increase in thyroid cancer after 
transplantation.
Contrary to some prior studies, (7–11) we found no association between polyclonal anti-T 
cell induction and NHL or VRCs in kidney recipients. Explanations for this discrepancy 
include less granular categorizations of induction therapies in previous studies (grouping 
polyclonal anti-T cell agents with muromonab-CD3) and differing outcomes of interest 
(PTLD). PTLD is a spectrum of different pathologic diagnoses with different mechanisms of 
development and risk profiles. NHL is the malignant end of the PTLD spectrum and, after 
non-melanoma skin cancers, the most common malignancy after transplantation. (19) Poor 
immune control of EBV has been linked to increased risk for NHL, driving the hypothesis of 
an association between antibody induction and NHL after transplantation. (18) Previous 
studies that separated polyclonal anti-T cell induction from muromonab-CD3 were 
consistent with our findings and did not demonstrate an association between polyclonal anti-
T cell induction and NHL after transplantation. (7,16,20,21)
Polyclonal anti-T cell antibody induction was associated with increased melanoma among 
non-Hispanic white kidney recipients. Most previous reports demonstrate no significant 
associations between polyclonal anti-T cell induction and grouped non-VRCs, but have not 
studied melanoma separately. (10,12,22)When we restrict analysis to recipients after 1999 or 
to those patients that received ATG, this association is of similar magnitude but no longer 
significant. This could represent decreased power to detect differences and decreased 
follow-up time. Increased melanoma has been demonstrated in other immunocompromised 
populations including patients with human immunodeficiency virus (HIV). (3,23) Melanoma 
is not known to be an infection related cancer. The link between melanoma and polyclonal 
anti-T cell induction may provide further clues into the relationship between melanoma and 
the immune system. Screening for melanoma is based on regular skin examinations, which 
is already part of clinical practice after transplantation due to the elevated risk of non-
melanoma skin cancers in this population. (24) More frequent skin examinations may be 
warranted in those kidney recipients who underwent polyclonal anti-T cell induction.
There has been little controversy concerning the relationship between muromonab-CD3 and 
NHL after kidney transplantation, and our findings were consistent with previous studies. 
Those studies with a specific muromonab-CD3 category report risk ratios for NHL after 
kidney transplantation ranging from 1.72–2.81. (7,9,16) The relationship between 
muromonab-CD3 and all VRCs appears to be driven by its association with NHL, since we 
observed no association between muromonab-CD3 and non-NHL VRCs. The association of 
muronomab-CD3 with NHL is consistent with the perception of increased potency of 
muromonab-CD3 compared to polyclonal induction agents and has led to decreased use of 
this agent in recent years.
Previous studies exploring PTLD risk associated with alemtuzumab have been inconclusive. 
While one study using OPTN data did not find an association between alemtuzumab and 
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PTLD after kidney transplantation, (11) another using a more recent OPTN cohort did. (16) 
We found 79% increased NHL associated with alemtuzumab after kidney transplantation. 
The relationship of alemtuzumab with other cancers has not been previously explored, and a 
novel finding of our study is the association of alemtuzumab induction with increased 
colorectal and thyroid cancer in kidney recipients. Neither colorectal cancer nor thyroid 
cancer has been associated with immunosuppression due to HIV. (25) Of possible relevance, 
there have been recent findings suggesting a link between colorectal cancer and infection 
with Fusobacterium species. (26,27) However it is unclear why an infection-related cancer 
risk would be modestly increased in one set of immunosuppressed patients and not another, 
and what role alemtuzumab might have in further increasing this risk. With respect to 
thyroid cancer, in the first set of kidney recipients to receive alemtuzumab, there was a 
report of autoimmune thyroid disease in one of the nine patients four years after receiving 
alemtuzumab. (28) Alemtuzumab induction could increase the risk of autoimmune 
inflammatory processes in the thyroid, in turn increasing risk for thyroid cancer. It is also 
possible, however, that the increased detection of thyroid cancers in this population could be 
an artifact of increased screening in this context. (29) Alternatively, there may be intrinsic 
oncogenic properties of alemtuzumab that have not been noted.
Our study addresses some of the major limitations of prior post-transplant cancer studies, 
including sample size, lack of long-term follow-up, and incomplete ascertainment of cancer 
outcomes. Because of increased sample size, we were able to test associations between more 
clinically and mechanistically homogenous categorizations of induction agents (including 
alemtuzumab) than previous reports. We were also able to analyze associations with several 
individual cancers with increased incidence following transplantation. Our findings for 
grouped VRCs should be considered with caution, because these cancer types differ in their 
etiology and it is possible that induction agents affect immune control of each virus in 
diverse ways.
There are a number of important limitations of our study to consider. There is a possibility 
of underreporting of both incident cancer and induction medication. The cancer registries 
used are population based registries with mandatory reporting of all incident cancers, but it 
is possible that transplant recipients may have moved away from states with mandatory 
reporting or linkage. In previous analysis, the rate of emigration is estimated to be 5.8% at 
10 years after transplant. (2) The duration of follow-up was limited for some transplant 
recipients, which affected our ability to look at associations of induction with long-term 
cancer risk. There could also be underreporting or misclassification of induction medications 
in the SRTR. We were not able to control for dose and administration schedule of induction 
medications or subsequent treatment with the same medications for rejection. Because of 
difference in rejection rates by immunosuppression protocols, and subsequent need for 
additional immunosuppression based on rejection rates, an intention-to-treat design was 
chosen. In other words, patients who received antibody agents for subsequent rejection 
episodes were classified by their original induction protocol. It is important to note that the 
cancer registries used do not capture non-melanoma skin cancers and we were unable to 
make any conclusions on these cancers despite the high risk and incidence of these cancers 
after transplantation. Finally, we make a number of comparisons throughout this study. 
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Given these multiple comparisons, there is a risk of alpha inflation, that is detecting 
significant relationships where they do not exist.
We have shown in a large, population-based cohort of kidney recipients, that there is little 
evidence to support the concern for increased cancer risk with the most commonly used 
induction agents. Increased NHL was seen with muromonab-CD3, an agent that has 
generally been supplanted by polyclonal anti-T cell induction, and alemtuzumab, which 
remains in extremely limited use. Our findings highlight the need for continued surveillance 
of alemtuzumab and further research into the mechanisms for the increased risk across a 
diverse group of cancers after transplantation. Commonly used induction agents, including 
the most modern polyclonal anti-T cell and anti-IL2R agents, are largely safe with regard to 
cancer risk after transplantation. There might be a role for increased melanoma screening for 
those patients treated with polyclonal anti-T cell induction, although absolute risk for this 
malignancy remains relatively low. Treatment decisions regarding the use of these agents 
should focus more on the balance between rejection prevention and acute infection rather 
than the risk of malignancy.
Materials and Methods
Transplant Cancer Match Study
The TCM Study (http://transplantmatch.cancer.gov/) links transplant records from the SRTR 
to 15 state and regional population-based U.S. cancer registries with mandatory reporting of 
all cancers except basal cell and squamous cell skin cancer. Currently the TCM Study 
includes 43% of the U.S. transplant population between 1987 and 2009. The study was 
approved by human subjects committees at the National Cancer Institute and, as required, at 
participating cancer registries.
Study Population and Exposure Definition
Kidney recipients transplanted between 1987 and 2009 in the TCM Study, with cancer 
registry coverage at the time of transplant, were included. When listing immunosuppression, 
centers specify if each agent was used for induction, maintenance, or rejection treatment; an 
agent was considered “induction” if the purpose was listed as induction and if usage 
occurred during the initial transplant hospitalization. Those recipients listed as having 
received more than one induction agent were excluded (~2%). Antibody induction agents 
were classified as polyclonal anti-T cell (anti-lymphocyte globulin, equine anti-thymocyte 
globulin, and rabbit anti-thymocyte globulin), muromonab-CD3 (monoclonal anti-T cell), 
alemtuzumab (anti-CD52), or anti-IL2R (IL-2 receptor inhibitors daclizumab and 
basiliximab). Patients who received antibody agents for subsequent rejection episodes were 
classified by their original induction protocol.
Cancer Outcomes
Cancers in kidney recipients were identified through linked records in participating cancer 
registries. Recipients were considered at risk from transplantation until the earliest of graft 
failure, retransplantation, death, loss to follow-up, or end of cancer registry coverage. The 
outcomes of interest were specific cancers that are common and occur with increased 
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incidence after transplantation: NHL and cancers of the lung, colorectum, kidney, and 
thyroid among the entire study population, and melanoma among non-Hispanic white 
recipients. Among transplant recipients, most NHLs are caused by Epstein-Barr virus 
(EBV). (18) We grouped together other virus-related cancers (VRCs) including Hodgkin 
lymphoma (EBV), cancers of the cervix, vagina, vulva, anus, penis, oropharynx, and tonsil 
(human papillomavirus), Kaposi sarcoma (human herpes virus 8), and liver cancer (hepatitis 
B, hepatitis C) for a composite outcome because they were too uncommon to examine 
separately.
Statistical Analysis
Multivariable Poisson regression models were used to quantify the risk of incident cancers 
associated with induction therapy. In each model, we compared risk in transplants treated 
with one type of antibody induction with transplants not treated with any induction. Models 
were adjusted for age at transplantation, gender, race, retransplantation, zero HLA mismatch 
status, receipt of a living donor kidney and year of transplantation. It has been demonstrated 
that there are different risk factors for early vs. late NHL and it might be expected that 
antibody immunosuppression would especially increase risk early after transplantation. (15) 
We assessed whether the effect of antibody induction on NHL risk differed early (≤2 years) 
and late after transplantation (>2 years) using an interaction term between the induction 
category and a time-varying marker for the first two years after transplantation. The use of 
antibody induction agents has changed over time. To take this into account, analyses for 
each category of induction immunosuppression were limited to those years for which at least 
20 recipients in the United States received that agent (polyclonal: 1987–2009; muromonab-
CD3: 1988–2003; alemtuzumab: 2001–2009; anti-IL2R: 1995–2009). Within the polyclonal 
anti-T cell induction category, induction with rabbit anti-thymocyte globulin (in particular 
ATG), has predominated since it gained U.S. Food and Drug Administration (FDA) 
approval in 1998; interestingly, FDA approval was given for treatment of rejection, and the 
highly prevalent use for induction is off-label. As additional sensitivity analyses, we looked 
only at those kidney recipients who received polyclonal anti-T induction after 1999 and only 
those kidney recipients who received ATG. All analyses were performed using Stata 
11.0/MP for Linux (StataCorp, College Station, TX, www.stata.com).
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Table 2
Association between induction therapy and incident virus-related cancers.
Cancers, N Incidencea aIRR (95% CI) P-Value
NHL
  No Induction 377 142.1 Reference
  Polyclonal 125 131.6 0.96 (0.77–1.20) 0.7
  Muromonab-CD3 80 210.9 1.37 (1.06–1.76) 0.02
  Alemtuzumab 15 216.2 1.79 (1.02–3.14) 0.04
  Anti-IL2R 96 114.9 0.82 (0.65–1.05) 0.1
Non-NHL VRCs
  No Induction 164 61.8 Reference
  Polyclonal 56 60.0 1.11 (0.82–1.53) 0.5
  Muromonab-CD3 25 65.9 1.02 (0.65–1.58) 0.9
  Alemtuzumab 4 57.6 2.05 (0.66–6.33) 0.2
  Anti-IL2R 53 63.5 1.09 (0.78–1.51) 0.6
All VRCs
  No Induction 541 203.9 Reference
  Polyclonal 181 190.6 1.01 (0.84–1.21) 0.9
  Muromonab-CD3 104 276.8 1.26 (1.01–1.57) 0.04
  Alemtuzumab 19 273.8 1.84 (1.11–3.03) 0.02
  Anti-IL2R 149 178.4 0.90 (0.74–1.10) 0.3
a
per 100,000 person-years
Adjusted incidence rate ratios for virus-related cancers after kidney transplantation. The number of cancers diagnosed in each stratum is shown (N). 
Virus-related cancers (VRCs) included non-Hodgkin lymphoma (NHL), Hodgkin lymphoma, HPV-related cancers (cancers of the cervix, vagina, 
vulva, anus, penis, oropharynx, and tonsil), Kaposi sarcoma, and liver cancer. All models were adjusted for recipient age, gender, race, 
retransplantation, zero HLA mismatch status, receipt of living donor kidney and year of transplant. Only transplants completed in years with at 
least 20 recipients receiving the induction therapy of interest were included: polyclonal 1987–2009, muromonab-CD3 1987–2003, alemtuzumab 
2001–2009, anti-IL2R 1995–2009.
Polyclonal anti-T cell = anti-lymphocyte globulin (ALG), equine anti-thymocyte globulin (ATGAM), and rabbit anti-thymocyte globulin (NRATG, 
NRATS, and ATG); Anti-IL2R = daclizumab and basiliximab; aIRR = adjusted incidence rate ratio; NHL = non-Hodgkin lymphoma; VRCs = 
non-Hodgkin lymphoma, Hodgkin lymphoma, HPV-related cancers (cancers of the cervix, vagina, vulva, anus, penis, oropharynx, and tonsil), 
Kaposi sarcoma, and liver cancer
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Table 3
Association between induction therapy and incident non-virus-related cancers.
Cancers, N Incidencea aIRR (95% CI) P-Value
Lung Cancer
  No Induction 297 111.9 Reference
  Polyclonal 127 133.7 1.14 (0.91–1.43) 0.2
  Muromonab-CD3 46 121.3 1.03 (0.75–1.41) 0.8
  Alemtuzumab 7 100.9 0.93 (0.42–2.07) 0.9
  Anti-IL2R 77 92.2 0.73 (0.56–0.95) 0.02
Kidney Cancer
  No Induction 261 98.4 Reference
  Polyclonal 121 127.4 1.08 (0.85–1.38) 0.5
  Muromonab-CD3 34 89.6 0.93 (0.65–1.34) 0.7
  Alemtuzumab 11 158.5 1.20 (0.63–2.30) 0.6
  Anti-IL2R 102 122.1 1.03 (0.81–1.32) 0.8
Colorectal Cancer
  No Induction 164 61.8 Reference
  Polyclonal 60 63.2 1.14 (0.82–1.58) 0.4
  Muromonab-CD3 20 52.7 0.77 (0.48–1.24) 0.3
  Alemtuzumab 7 100.9 2.46 (1.03–5.91) 0.04
  Anti-IL2R 47 56.3 0.88 (0.62–1.25) 0.5
Thyroid Cancer
  No Induction 103 38.8 Reference
  Polyclonal 26 27.4 0.65 (0.40–1.04) 0.07
  Muromonab-CD3 5 131.8 0.32 (0.12–0.80) 0.01
  Alemtuzumab 10 144.1 3.37 (1.55–7.33) 0.002
  Anti-IL2R 27 32.3 0.81 (0.51–1.29) 0.4
Melanomab
  No Induction 107 68.7 Reference
  Polyclonal 56 103.4 1.50 (1.06–2.14) 0.02
  Muromonab-CD3 11 51.1 0.77 (0.41–1.45) 0.4
  Alemtuzumab 3 81.1 1.14 (0.33–3.95) 0.8




among non-Hispanic white kidney recipients
Adjusted incidence rate ratios for non-virus-related cancers (non-VRC) after kidney transplantation. The number of cancers diagnosed in each 
stratum is shown (N). All models were adjusted for recipient age, gender, race, retransplantation, zero HLA mismatch status, receipt of living donor 
kidney and year of transplant. Only transplants completed in years with at least 20 recipients receiving the induction therapy of interest were 
included: polyclonal 1987–2009, muromonab-CD3 1987–2003, alemtuzumab 2001–2009, anti-IL2R 1995–2009.
Polyclonal anti-T cell = anti-lymphocyte globulin (ALG), equine anti-thymocyte globulin (ATGAM), and rabbit anti-thymocyte globulin (NRATG, 
NRATS, and ATG); Anti-IL2R = daclizumab and basiliximab; aIRR = adjusted incidence rate ratio
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